HIPEC for Ovarian Cancer

The University of Kansas Cancer Center, Kansas City, KS
Ovarian Cancer+2 More ConditionsHIPEC - Procedure

Study Summary

This trial will test if treating ovarian cancer with Heated Intraperitoneal Chemotherapy (HIPEC) followed by intravenous (IV) chemotherapy can start within 42 days of HIPEC.

Eligible Conditions
  • Ovarian Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to 2 years

30 days
Proportion of deaths occurring during post-hospital discharge period.
42 days
Time to start of intravenous (IV) chemotherapy.
90 days
Average number of hospital re-admissions.
Chemotherapy-related adverse events.
Proportion of deaths occurring during post-hospital discharge.
Up to 2 years
Average number of days in hospital Intensive Care Unit (ICU).
Average overall length of in-hospital stay.
Proportion of deaths occurring in hospital.

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

HIPEC + adjuvant IV chemotherapy
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: HIPEC · No Placebo Group · Phase 2

HIPEC + adjuvant IV chemotherapyExperimental Group · 3 Interventions: Carboplatin, Paclitaxel, HIPEC · Intervention Types: Drug, Drug, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

Andrea JewellLead Sponsor
University of Kansas Medical CenterOTHER
413 Previous Clinical Trials
160,721 Total Patients Enrolled
2 Trials studying Ovarian Cancer
52 Patients Enrolled for Ovarian Cancer
Andrea Jewell, MDPrincipal InvestigatorThe University of Kansas - Cancer Center

Eligibility Criteria

Age 18+ · Female Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not received the HIPEC treatment before.

Frequently Asked Questions

Is the enrollment period for this research study currently accessible to participants?

"As of today, this medical study is still recruiting participants. It was initially published on December 15th 2017 and the latest update to its page occurred on January 21st 2022." - Anonymous Online Contributor

Unverified Answer

How many individuals are being enrolled in this clinical experiment?

"Correct, according to records on clinicaltrials.gov this study is actively recruiting participants. It was first posted in December 2017 and most recently updated in January 2022 with the aim of enrolling 20 people at one site." - Anonymous Online Contributor

Unverified Answer

Has the use of HIPEC been examined in other research efforts?

"Presently, 1174 investigations into HIPEC are underway with 332 in their final phase. Of these trials, the majority originate from Shanghai; however, there exist 66513 different sites where such studies may be conducted." - Anonymous Online Contributor

Unverified Answer

Has the FDA given clearance to use HIPEC?

"HIPEC's safety has been largely corroborated in Phase 2 clinical trials, so it was rated a 2." - Anonymous Online Contributor

Unverified Answer

In what scenarios do medical professionals commonly deploy HIPEC treatments?

"HIPEC is a viable solution for managing the growth of melanoma, neoplasm metastasis, and non-Hodgkin's lymphoma." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.